291 results
Search Results
Now showing 1 - 10 of 291
Publication Open Access Preparing for introduction of a dengue vaccine: Recommendations from the 1st Dengue v2V Asia-Pacific Meeting(2011-11-28) Sai Kit Lam; Donald Burke; Maria Rosario Capeding; Chee Keong Chong; Laurent Coudeville; Jeremy Farrar; Duane Gubler; Sri Rezeki Hadinegoro; Jeffrey Hanna; Jean Lang; Han Lim Lee; Yee Sin Leo; Chan Quang Luong; Richard Mahoney; John Mcbride; Jorge Mendez Galvan; Lee Ching Ng; Suchitra Nimmannitya; Eng Eong Ooi; Donald Shepard; Jaco Smit; Rémy Teyssou; Laurent Thomas; Joseph Torresit; Pedro Vasconcelos; Dewa Nyoman Wirawan; Sutee Yoksan; Mahidol University. Institute of Molecular BiosciencesInfection with dengue virus is a major public health problem in the Asia-Pacific region and throughout tropical and sub-tropical regions of the world. Vaccination represents a major opportunity to control dengue and several candidate vaccines... are in development. Experts in dengue and in vaccine introduction gathered for a two day meeting during which they examined the challenges inherent to the introduction of a dengue vaccine into the national immunisation programmes of countries of the Asia-PacificPublication Metadata only Which dengue vaccine approach is the most promising, and should we be concerned about enhanced disease after vaccination?: The challenges of a dengue vaccine(2018-06-01) Gavin Screaton; Juthathip Mongkolsapaya; Imperial College London; Faculty of Medicine, Siriraj Hospital, Mahidol University© 2018 Cold Spring Harbor Laboratory Press; All rights reserved. A dengue vaccine has been pursued for more than 50 years and, unlike other flaviviral vaccines such as that against yellowfever, progress has been slow. In this review, we describe... progress toward the first licensed dengue vaccine Dengvaxia, which does not give complete protection against disease. The antibody response to the dengue virion is reviewed, highlighting immunodominant yet poorly neutralizing responses in the context of aPublication Metadata only Dengue virus specific T cell responses to live attenuated monovalent dengue-2 and tetravalent dengue vaccines(2000-12-01) J. Rabablert; T. Dharakul; S. Yoksan; N. Bhamarapravati; Mahidol UniversityThe proliferative T cell responses to dengue vaccines were studied using the parental strains of dengue vaccines as antigens in 26 dengue immune individuals who resided in Bangkok which is the endemic area of dengue infection. The magnitude... of the antibody. Evaluation of the proliferative T cell responses in 8 recipients of the monovalent dengue-2 (16681-PDK53) or the tetravalent dengue vaccines demonstrated that both vaccines induced high levels of neutralizing antibody as well as high levelsPublication Metadata only Detection of dengue cases by serological testing in a dengue vaccine efficacy trial: Utility for efficacy evaluation and impact of future vaccine introduction(2016-05-23) Eric Plennevaux; Arunee Sabchareon; Kriengsak Limkittikul; Pornthep Chanthavanich; Chukiat Sirivichayakul; Annick Moureau; Mark Boaz; T. Anh Wartel; Melanie Saville; Alain Bouckenooghe; Sanofi Pasteur SA; Mahidol University; Sanofi Pasteur; Clinical Sciences and Medical Affairs Asiaidentified serological based diagnosis as a potential tool to define probable dengue cases in the context of vaccine trials, while acknowledging that this may have to be interpreted with caution. Methods: In a phase IIb randomized, placebo-controlled trial... assessing the efficacy of a tetravalent dengue vaccine (CYD-TDV) in Thai schoolchildren, case definition was based on virological confirmation by either serotype-specific RT-PCRs or by NS1-antigen ELISA (Clinicaltrials.gov NCT00842530). Here, wePublication Metadata only Targets and strategies for vaccine development against dengue viruses(2021-12-01) Wen Hung Wang; Aspiro Nayim Urbina; Chih Yen Lin; Zih Syuan Yang; Wanchai Assavalapsakul; Arunee Thitithanyanont; Po Liang Lu; Yen Hsu Chen; Sheng Fan Wang; Kaohsiung Medical University Chung-Ho Memorial Hospital; Chulalongkorn University; Mahidol University; Kaohsiung Medical University) is asymptomatic and self-limiting in most people with first infection, increased severe dengue symptoms may be observed in people with heterotypic secondary DENV infection. Since there is a lack of specific antiviral medication, the development of dengue vaccines... is critical in the prevention and control this disease. Several targets and strategies in the development of dengue vaccine have been demonstrated. Currently, Dengvaxia, a live-attenuated chimeric yellow-fever/tetravalent dengue vaccine (CYD-TDV) developedPublication Metadata only Dengue vaccine trial guidelines and role of large-scale, post proof-of-concept demonstration projects in bringing a dengue vaccine to use in dengue endemic areas(2010-01-01) G. William Letson; Pratap Singhasivanon; Eduardo Fernandez; Nihal Abeysinghe; Juan Jose Amador; Harold S. Margolis; Robert Edelman; International Vaccine Institute, Seoul; Mahidol University; Brock University; Ministry of Health Sri Lanka; Program for Appropriate Technology in Health (PATH); University of Maryland School of MedicineIn this review, we consider the issues impacting conduct and design of dengue vaccine trials with reference to the recently published World Health Organization "Guidelines for Conduct of Clinical Trials of Dengue Vaccines in Endemic Areas." We... discuss logistic, scientific and ethical challenges concerning evaluation and introduction of dengue vaccines; these range from randomized trials that establish "proof of concept" of vaccine efficacy, to post-"proof of concept" trials, particularlyItem Metadata only Japanese Encephalitis DNA Vaccines with Epitope Modification Reduce the Induction of Cross-Reactive Antibodies against Dengue Virus and Antibody-Dependent Enhancement of Dengue Virus Infection(2022-09-01) Kotaki T.; Nagai Y.; Yamanaka A.; Konishi E.; Kameoka M.; Mahidol UniversityInfection with viruses belonging to the genus Flavivirus, such as Japanese encephalitis virus (JEV) and dengue virus (DENV), is a worldwide health problem. Vaccines against JEV and DENV are currently available. However, the dengue vaccine possibly... increases the risk of severe dengue due to antibody-dependent enhancement (ADE). Moreover, the Japanese encephalitis (JE) vaccine reportedly induces cross-reactive ADE-prone antibodies against DENV, potentially leading to symptomatic dengue. ThereforePublication Metadata only Dynamics of susceptibility and transmissibility of the live, attenuated, candidate vaccines dengue-1 PDK13, dengue-3 PGMK30F3, and dengue-4 PDK48 after oral infection in Aedes aegypti(1999-01-01) Nuananong Jirakanjanakit; Mi Mi Khin; Sutee Yoksan; Natth Bhamarapravati; Mahidol University. In general, infection and dissemination rates were poorer for the vaccine compared with the parent viruses. The transmissibility was also lower for dengue-1 PDK13 than the parent virus, whereas it was not detected for isolates from vaccinees and dengue-3 PGMK...30F3. Transmissibility of dengue-4 PDK48 was not determined because no dissemination occurred. Replication rates of vaccine strains were also found to be less efficient than the parent viruses. These imply that vaccination with the candidate vaccinePublication Metadata only Monoclonal antibody-based capture ELISA in the diagnosis of previous dengue infection(2019-10-29) Chukiat Sirivichayakul; Kriengsak Limkittikul; Pornthep Chanthavanich; Sutee Yoksan; Anuttarasakdi Ratchatatat; Jacqueline Kyungah Lim; Watcharee Arunsodsai; Arunee Sabchareon; International Vaccine Institute, Seoul; Thailand Ministry of Public Health; Mahidol University© 2019 The Author(s). Background: Dengue is an important mosquito-borne disease. There is currently only one licensed vaccine for dengue prevention. The vaccine provides higher efficacy in pre-vaccination dengue-seropositive persons but a higher... risk of subsequent more severe dengue in dengue-seronegative persons. It is recommended that the dengue vaccine may be given in dengue-seropositive individuals or as mass vaccination without individual pre-vaccination screening in areas where the denguePublication Metadata only Immune response and occurrence of dengue infection in Thai children three to eight years after vaccination with live attenuated tetravalent dengue vaccine(2006-07-01) Pornthep Chanthavanich; Christine Luxemburger; Chukiat Sirivichayakul; Keswadee Lapphra; Krisana Pengsaa; Sutee Yoksan; Arunee Sabchareon; Jean Lang; Sanofi Pasteur SA; Mahidol University; The Institute of Science and Technology for Research and Development, Mahidol University; Sanofi PasteurFrom 1992 to 1997, 140 Thai children 4-15 years of age received an investigational live attenuated tetravalent dengue vaccine (LATDV). These children were contacted 3-8 years later in 2001 to assess humoral immunity and investigate whether they were... subsequently at higher risk of developing severe dengue. One hundred thirteen were successfully contacted and participated in this retrospective cohort study with two age- and address-matched controls per vaccinee. The number of vaccinated subjects